BONESUPPORT Q4: Operating leverage set to accelerate - Redeye
Redeye returns with more flesh on the bone regarding the Q4 report. While strong Fx tailwinds boosted the EBIT beat, we overlook our OPEX assumptions and update our WACC to 8% (9%). We raise our fair value range.
ANNONS
Redeye returns with more flesh on the bone regarding the Q4 report. While strong Fx tailwinds boosted the EBIT beat, we overlook our OPEX assumptions and update our WACC to 8% (9%). We raise our fair value range.
